Creso Pharma (ASX:CPH) completes Halucenex acquisition

• Creso Pharma's (CPH) acquisition of Canadian psychadelics company Halucenex Life Sciences is now complete
• The cannabis business paid $500,000 cash and handed over 29.2 million CPH shares and 17.5 million performance shares to acquire Halucenex
• It says the Candian company will give it access to the growing global psychedelics market, estimated to be worth US$100 billion (A$133.8 billion)
• Halucenex is gearing up to run a phase two clinical trial testing psilocybin, the ingredient in magic mushrooms, on those with PTSD

Read the Full Article on The Market Herald here